ATE253893T1 - Zusammensetzungen enthaltend ein peptid und polymilch-glykolsäure geeignet für die herstellung von subkutanen implantaten mit verlängerter wirkstoffabgabe - Google Patents

Zusammensetzungen enthaltend ein peptid und polymilch-glykolsäure geeignet für die herstellung von subkutanen implantaten mit verlängerter wirkstoffabgabe

Info

Publication number
ATE253893T1
ATE253893T1 AT99963398T AT99963398T ATE253893T1 AT E253893 T1 ATE253893 T1 AT E253893T1 AT 99963398 T AT99963398 T AT 99963398T AT 99963398 T AT99963398 T AT 99963398T AT E253893 T1 ATE253893 T1 AT E253893T1
Authority
AT
Austria
Prior art keywords
peptide
polylactic
glycolic acid
production
compositions containing
Prior art date
Application number
AT99963398T
Other languages
English (en)
Inventor
Alain Maquin
Patrice Mauriac
Pierre Marion
Original Assignee
Mediolanum Farmaceutici Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mediolanum Farmaceutici Srl filed Critical Mediolanum Farmaceutici Srl
Application granted granted Critical
Publication of ATE253893T1 publication Critical patent/ATE253893T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT99963398T 1998-12-10 1999-12-06 Zusammensetzungen enthaltend ein peptid und polymilch-glykolsäure geeignet für die herstellung von subkutanen implantaten mit verlängerter wirkstoffabgabe ATE253893T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1998MI002655A IT1304152B1 (it) 1998-12-10 1998-12-10 Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
PCT/EP1999/009536 WO2000033809A1 (en) 1998-12-10 1999-12-06 Compositions containing a peptide and polylactic-glycolic acid suitable for preparing subcutaneous implants with an extended release period

Publications (1)

Publication Number Publication Date
ATE253893T1 true ATE253893T1 (de) 2003-11-15

Family

ID=11381206

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99963398T ATE253893T1 (de) 1998-12-10 1999-12-06 Zusammensetzungen enthaltend ein peptid und polymilch-glykolsäure geeignet für die herstellung von subkutanen implantaten mit verlängerter wirkstoffabgabe

Country Status (16)

Country Link
US (1) US6620422B1 (de)
EP (1) EP1137400B1 (de)
JP (1) JP4607329B2 (de)
KR (1) KR100676844B1 (de)
CN (1) CN1149975C (de)
AT (1) ATE253893T1 (de)
AU (1) AU757898C (de)
BR (1) BR9916053B1 (de)
CA (1) CA2354034C (de)
DE (1) DE69912836T2 (de)
DK (1) DK1137400T3 (de)
ES (1) ES2211211T3 (de)
IT (1) IT1304152B1 (de)
PT (1) PT1137400E (de)
TW (1) TW561053B (de)
WO (1) WO2000033809A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000156A1 (en) 2001-06-22 2003-01-03 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
EP1411861B1 (de) 2001-06-29 2012-04-04 Medgraft Microtech, Inc. Biologisch abbaubare injizierbare implantate und verwandte herstellungs- und verwendungsmethoden
KR100885070B1 (ko) * 2002-05-08 2009-02-25 재단법인서울대학교산학협력재단 Ｐｌｇａ에 특이적으로 부착하는 올리고 펩타이드
KR101041767B1 (ko) * 2002-06-25 2011-06-17 다케다 야쿠힌 고교 가부시키가이샤 서방성 조성물의 제조 방법
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1911763B1 (de) 2003-01-28 2010-08-11 Ironwood Pharmaceuticals, Inc. Zusammensetzungen zur Behandlung von Magen-Darm-Störungen
GB0304726D0 (en) * 2003-03-01 2003-04-02 Ardana Bioscience Ltd New Process
ITMI20031302A1 (it) * 2003-06-26 2004-12-27 Mediolanum Pharmaceuticals Ltd Uso di etanolo come plasticizzante per preparare impianti sottocutanei contenenti principi attivi termolabili dispersi in una matrice di plga.
CA2530120A1 (en) * 2003-06-26 2005-01-06 Mediolanum Pharmaceuticals Ltd. Subcutaneous implants having limited initial release of the active principle and subsequent linearly varying extended release thereof
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
CA2544678C (en) 2003-11-05 2013-12-31 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
CN100534527C (zh) * 2003-12-30 2009-09-02 杜雷科特公司 用于控制释放优选为GnRH的活性剂的优选含有PEG和PLG的混合物的聚合植入物
AU2004313245B2 (en) * 2003-12-30 2011-04-14 Durect Corporation Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH
FR2865938B1 (fr) * 2004-02-05 2006-06-02 Sod Conseils Rech Applic Formulation retard solide comprenant de l'acetate de triptoreline
WO2006078320A2 (en) 2004-08-04 2006-07-27 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
EP1835885A1 (de) * 2004-12-23 2007-09-26 Durect Corporation Polymer-implantate, vorzugsweise mit einem gemisch aus peg und plg für die kontrollierte freisetzung eines gnrh
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
ITMI20061545A1 (it) * 2006-08-02 2008-02-03 Mediolanum Pharmaceuticals Ltd Particelle in grado di rilasciare il principio attivo per un periodo prolungato di tempo
ITMI20061539A1 (it) * 2006-08-02 2008-02-03 Mediolanum Pharmaceuticals Ltd Impianti sottocutanei in grado di rilasciare il principio attivo per un periodo prolungato di tempo
ITMI20061538A1 (it) * 2006-08-02 2008-02-03 Mediolanum Pharmaceuticals Ltd Impianti sottocutanei in grado di rilasciare il principio attivo per un periodo prolungato di tempo
CN101209238B (zh) * 2006-12-27 2012-05-09 辽宁省计划生育科学研究院 含孕二烯酮的生物降解型长效皮下避孕埋植剂及其制备
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8067028B2 (en) * 2007-08-13 2011-11-29 Confluent Surgical Inc. Drug delivery device
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
WO2009085952A1 (en) 2007-12-20 2009-07-09 Brookwood Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2009128932A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Delivery of lfa-1 antagonists to the gastrointestinal system
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2246063A1 (de) * 2009-04-29 2010-11-03 Ipsen Pharma S.A.S. GnRH Analoge enthaltende Retardformulierungen
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2011161531A1 (en) 2010-06-24 2011-12-29 Torrent Pharmaceuticals Limited Pharmaceutical composition containing goserelin for in-situ implant
WO2012151343A1 (en) 2011-05-04 2012-11-08 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
DE102011114864A1 (de) 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
KR20200108932A (ko) 2012-07-25 2020-09-21 에스에이알코드 바이오사이언스 인코포레이티드 Lfa-1 저해제 및 그의 다형체
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
CN103446041B (zh) * 2013-08-27 2015-06-10 青岛东辉医药科技发展有限公司 一种亮丙瑞林缓控释药棒及其制备方法
JP6661531B2 (ja) 2013-10-10 2020-03-11 シナジー ファーマシューティカルズ インコーポレイテッド オピオイド誘発性機能障害の治療に有用なグアニル酸シクラーゼのアゴニスト
CN105287390A (zh) * 2015-11-20 2016-02-03 北京博恩特药业有限公司 一种长效醋酸亮丙瑞林微球及其制备方法
CN105267153B (zh) * 2015-11-27 2018-05-11 上海苏豪逸明制药有限公司 一种曲普瑞林缓释微粒及其制备方法
US10653744B2 (en) 2016-01-11 2020-05-19 Bausch Health Ireland Limited Formulations and methods for treating ulcerative colitis
CN105878174B (zh) * 2016-04-26 2021-06-29 广州帝奇医药技术有限公司 一种固体分散体及其制备方法与应用
CN107281493A (zh) * 2017-06-20 2017-10-24 苏州乔纳森新材料科技有限公司 一种聚乳酸‑聚乙醇酸共聚复合材料及其制备方法
WO2026050206A1 (en) 2024-08-27 2026-03-05 Ironwood Pharmaceuticals, Inc. Combinations of glp-1 and guanylate cyclase c (gc-c) receptor agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH679207A5 (de) * 1989-07-28 1992-01-15 Debiopharm Sa
AU653771B2 (en) * 1991-01-03 1994-10-13 Alkermes Controlled Therapeutics, Inc. Stabilization of proteins by cationic biopolymers
IE920040A1 (en) * 1991-01-09 1992-07-15 Alza Corp Bioerodible devices and compositions for diffusional release¹of agents
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5945128A (en) * 1996-09-04 1999-08-31 Romano Deghenghi Process to manufacture implants containing bioactive peptides
JP2001505899A (ja) * 1996-12-12 2001-05-08 デーデーエス ドラッグ デリバリー サービス ゲセルシャフト ツーア フェアデルング デア フォルシュング イン ファーマシューティッシャー テクノロジー ウント バイオファーマジー エムベーハー 任意に活性物質を含むマトリクス材料−賦形剤コンパウンドの形態の処方物

Also Published As

Publication number Publication date
ES2211211T3 (es) 2004-07-01
CN1149975C (zh) 2004-05-19
BR9916053B1 (pt) 2011-04-19
PT1137400E (pt) 2004-03-31
DK1137400T3 (da) 2004-03-22
WO2000033809A1 (en) 2000-06-15
KR20010082310A (ko) 2001-08-29
JP2002531486A (ja) 2002-09-24
DE69912836T2 (de) 2004-11-11
DE69912836D1 (de) 2003-12-18
IT1304152B1 (it) 2001-03-08
CA2354034A1 (en) 2000-06-15
EP1137400B1 (de) 2003-11-12
AU1971100A (en) 2000-06-26
CA2354034C (en) 2009-01-27
US6620422B1 (en) 2003-09-16
ITMI982655A1 (it) 2000-06-10
KR100676844B1 (ko) 2007-01-31
CN1329485A (zh) 2002-01-02
AU757898B2 (en) 2003-03-13
TW561053B (en) 2003-11-11
BR9916053A (pt) 2001-09-04
AU757898C (en) 2003-12-18
JP4607329B2 (ja) 2011-01-05
EP1137400A1 (de) 2001-10-04

Similar Documents

Publication Publication Date Title
ATE253893T1 (de) Zusammensetzungen enthaltend ein peptid und polymilch-glykolsäure geeignet für die herstellung von subkutanen implantaten mit verlängerter wirkstoffabgabe
BR9910251A (pt) Estimulação hematopoiética
ATE249422T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
AU3310595A (en) Compositions and methods for identifying biologically active molecules
EP0283713A3 (en) Complexes of saponins with phospholipids and pharmaceutical and cosmetic compositions containing them
MX9705710A (es) Compuestos con propiedades de liberacion de la hormona del crecimiento.
HUT47863A (en) Process for production of stabilized human protein compositions
BRPI0004827B8 (pt) complexo à base de ácido ortossilícico biologicamente assimilável, processo de preparação do mesmo, composição cosmética ou farmacêutica, e, complemento nutritivo
DE69109284D1 (de) Verwendung von fluorierten löslichen tensiden zur herstellung von aerosolarzneimitteln mit dosierter abgabe.
DE69925276D1 (de) Stoffe und zusammensetzungen für die verabreichung aktiver substanzen
DE69738961D1 (de) Screening von verbindungen zu ihrer fähigkeit um die herstellung von beta-amyloid peptiden zu veränderen
ATE177757T1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
DE69427650D1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
DE69619860D1 (de) Verfahren zur herstellung aktiver substanzen aus perlmutt, resultierende produkte, geeignet für medizinische anwendungen
TR199700834T1 (xx) 1-Aril-2-Akilamino ethan bile�ikleri ve bunlar�n n�rokinin olarak �zellikle n�rokinin 1 has�mlar� olarak kullan�mlar�.
BR0111506A (pt) Complexos de droga macromoleculares e composições contendo os mesmos
ES8602617A1 (es) Un procedimiento para la produccion de peptidos.
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
EP0672052A1 (de) Tachyquinin antagonisten, ihre herstellung und ihre verwendung in pharmazeutischen formulierungen.
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
ES2170144T3 (es) Variantes que no se empalman de gp350/220.
CO5050337A1 (es) Composiciones farmaceuticas que incluyen polipeptidos il-18 y preparacion de la misma
DE50114335D1 (de) Lh-rh-antagonisten, deren herstellung und verwendung als arzneimittel
ATE216234T1 (de) Zusammensetzungen aus aminosäure zur behandlung von infektionen
ES2166800T3 (es) Procedimiento para la preparacion de o,s-acetales de 2,2-difluoroceteno sililo y o,s-esteres del acido alfa,alfa-difluoro-beta-sililoxi-1,3-dioxolan-4-propanoico.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1137400

Country of ref document: EP